The float from ongoing dilution is a noose around their neck. This will permanently go away after the tech is approved and unexpectedly large sales are rolling in or after a reverse split to get us to NASDAQ - assuming the company doesn't get acquired. Company still has an uphill battle. FDA needs to green light with an ER or IR approval.